CurveBeam AI (ASX:CVB) ROC (Joel Greenblatt) %: -163.99% (As of Dec. 2025)


What is CurveBeam AI ROC (Joel Greenblatt) %?

CurveBeam AI ASX:CVB ROC (Joel Greenblatt) % is -163.99% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 840 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 77.62% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CurveBeam AI's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -163.99%.

The historical rank and industry rank for CurveBeam AI's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:CVB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3969.98   Med: -394.5   Max: -133.54
Current: -133.54

During the past 5 years, CurveBeam AI's highest ROC (Joel Greenblatt) % was -133.54%. The lowest was -3969.98%. And the median was -394.50%.

ASX:CVB's ROC (Joel Greenblatt) % is ranked worse than
77.62% of 840 companies
in the Medical Devices & Instruments industry
Industry Median: 4.035 vs ASX:CVB: -133.54

CurveBeam AI's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


CurveBeam AI  (ASX:CVB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


CurveBeam AI ROC (Joel Greenblatt) % Related Terms


CurveBeam AI ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for CurveBeam AI's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CurveBeam AI ROC (Joel Greenblatt) % Chart

CurveBeam AI Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
0.00 0.00 -3,969.98 -394.50 -176.73

CurveBeam AI Semi-Annual Data
Jun21 Dec21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only -640.58 -207.78 -189.91 -118.70 -163.99

ASX:CVB vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, CurveBeam AI's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CurveBeam AI ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where CurveBeam AI's ROC (Joel Greenblatt) % falls into.



CurveBeam AI ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.244 + 10.257 + 1.824) - (2.372 + 0 + 4.047)
=5.906

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.294 + 10.073 + 1.407) - (2.514 + 0 + 3.766)
=11.494

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of CurveBeam AI for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-18.82/( ( (2.641 + max(5.906, 0)) + (2.911 + max(11.494, 0)) )/ 2 )
=-18.82/( ( 8.547 + 14.405 )/ 2 )
=-18.82/11.476
=-163.99 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -163.99% mean?
CurveBeam AI (ASX:CVB) has a ROC (Joel Greenblatt) % of -163.99% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CurveBeam AI and its competitors. According to the industry distribution chart, CurveBeam AI ranks #652 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 77.6%.
Is CurveBeam AI's ROC (Joel Greenblatt) % too high?
CurveBeam AI's current ROC (Joel Greenblatt) % is -163.99%. Based on the distribution chart, CurveBeam AI ranks #652 out of 840 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #652 out of 840 companies for ROC (Joel Greenblatt) %. This places CurveBeam AI in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current ROC (Joel Greenblatt) % is -163.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current ROC (Joel Greenblatt) % of -163.99%. The current ROC (Joel Greenblatt) % is -163.99%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current ROC (Joel Greenblatt) % is -163.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CurveBeam AI Business Description

Address 10 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.